AAV-mediated gene therapy for atherosclerosis

Current Atherosclerosis Reports

Volumn 16, Issue 9, 2014, Pages

  Lehrke, Michael ^a   Lebherz, Corinna ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Adeno associated virus; Atherosclerosis; Diabetes; Gene therapy; Ischemic cardiomyopathy

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR 1; ADENO ASSOCIATED VIRUS VECTOR 2; ADENO ASSOCIATED VIRUS VECTOR 5; ADENO ASSOCIATED VIRUS VECTOR 7; ADENO ASSOCIATED VIRUS VECTOR 8; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN E; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INTERLEUKIN 10; LOW DENSITY LIPOPROTEIN RECEPTOR; PARVOVIRUS VECTOR; SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ADENO ASSOCIATED VIRUS; ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISEASE COURSE; GENE THERAPY; GENE TRANSFER; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; ISCHEMIC CARDIOMYOPATHY; NONHUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR; VIRAL GENE DELIVERY SYSTEM; ANIMAL; DEPENDOPARVOVIRUS; GENETICS; HEART FAILURE; MYOCARDIAL ISCHEMIA; STROKE;

ANIMALS; ATHEROSCLEROSIS; DEPENDOVIRUS; GENETIC THERAPY; HEART FAILURE; HUMANS; MYOCARDIAL ISCHEMIA; STROKE;

EID: 84905318760     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-014-0434-0     Document Type: Review

References (53)

1. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med. 2013;15:65-77.
2. Douglas JT. Adenoviral vectors for gene therapy. Mol Biotechnol. 2007;36:71-80. (Pubitemid 350133603)
3. Lewinski MK, Yamashita M, Emerman M, Ciuffi A, Marshall H, Crawford G, et al. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog. 2006;2:e60.
4. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002;99:11854-9. (Pubitemid 34994488)
5. Bartel M, Schaffer D, Buning H. Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity. Front Microbiol. 2011;2:204.
6. McCarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther J Am Soc Gene Ther. 2008;16:1648-56.
7. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adenoassociated viruses. J Infect Dis. 2009;199:381-90.
8. Calcedo R, Wilson JM. Humoral immune response to AAV. Front Immunol. 2013;4:341.
9. Selot RS, Hareendran S, Jayandharan GR. Developing immunologically inert adeno-associated virus (AAV) vectors for gene therapy: possibilities and limitations. Curr Pharm Biotechnol. 2014.
10. Sniderman AD, Tsimikas S, Fazio S. Severe hypercholesterolemia phenotype: clinical diagnosis, Management and emerging therapies. J Am Coll Cardiol. 2014.
11. Grossman M, Raper SE, Kozarsky K, Stein EA, Engelhardt JF, Muller D, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet. 1994;6: 335-41. (Pubitemid 24190015)
12. Chen SJ, Rader DJ, Tazelaar J, Kawashiri M, Gao G, Wilson JM. Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor. Mol Ther J Am Soc Gene Ther. 2000;2:256-61.
13. Lebherz C, Gao G, Louboutin JP, Millar J, Rader D, Wilson JM. Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J Gene Med. 2004;6:663-72. (Pubitemid 40228082)
14. Kassim SH, Li H, Bell P, Somanathan S, Lagor W, Jacobs F, et al. Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia. Hum Gene Ther. 2013;24:19-26.
15. Kitajima K, Marchadier DH, Miller GC, Gao GP, Wilson JM, Rader DJ. Complete prevention of atherosclerosis in apoE-deficient mice by hepatic human apoE gene transfer with adeno-associated virus serotypes 7 and 8.Arterioscler Thromb Vasc Biol. 2006;26:1852-7. (Pubitemid 44305340)
16. Evans V, Foster H, Graham IR, Foster K, Athanasopoulos T, Simons JP, et al. Human apolipoprotein E expression from mouse skeletal muscle by electrotransfer of nonviral DNA (plasmid) and pseudotyped recombinant adeno-associated virus (AAV2/7). Hum Gene Ther. 2008;19:569-78. (Pubitemid 351913528)
17. Flotte TR, Trapnell BC, Humphries M, Carey B, Calcedo R, Rouhani F, et al. Phase 2 clinical trial of a recombinant adenoassociated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther. 2011;22:1239-47.
18. Zhou J, Xu L, Huang RS, Huang Y, Le Y, Jiang D, et al. Apolipoprotein A5 gene variants and the risk of coronary heart disease: a casecontrol study and metaanalysis. Mol Med Rep. 2013;8:1175-82.
19. Sharma V, Beckstead JA, Simonsen JB, Nelbach L, Watson G, Forte TM, et al. Gene transfer of apolipoprotein A-V improves the hypertriglyceridemic phenotype of apoa5 (-/-) mice. Arterioscler Thromb Vasc Biol. 2013;33:474-80.
20. Kitajima K, Marchadier DH, Burstein H, Rader DJ. Persistent liver expression of murine apoA-l using vectors based on adenoassociated viral vectors serotypes 5 and 1. Atherosclerosis. 2006;186:65-73.
21. Vaessen SF, Veldman RJ, Comijn EM, Snapper J, Sierts JA, van den Oever K, et al. AAV gene therapy as a means to increase apolipoprotein (Apo) A-I and high-density lipoprotein-cholesterol levels: correction of murine ApoA-I deficiency. J Gene Med. 2009;11:697-707.
22. Lebherz C, Sanmiguel J, Wilson JM, Rader DJ. Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovasc Diabetol. 2007;6:15.
23. Koornneef A, Maczuga P, van Logtenstein R, Borel F, Blits B, Ritsema T, et al. Apolipoprotein B knockdown by AAV-delivered shRNA lowers plasma cholesterol in mice. Mol Ther J Am Soc Gene Ther. 2011;19:731-40. This study proves that AAV-mediated gene therapy can also be used to knock down selected genes by combining the tools of viral gene transfer and RNA interference.
24. Maczuga P, Verheij J, van der Loos C, van Logtenstein R, Hooijer G, Martier R, et al. Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver. Gene Ther. 2014;21:60-70.
25. McGowan MP, Tardif JC, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE. 2012;7:e49006.
26. Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013;62:2178-84.
27. Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126:2283-92.
28. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014;383:60-8.
29. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA J Am Med Assoc. 2014;311:1870-82.
30. Kastelein JJ, Robinson JG, Farnier M, Krempf M, Langslet G, Lorenzato C, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther/Sponsored Int Soc Cardiovasc Pharmacother. 2014.
31. Grimm D, Kay MA. RNAi and gene therapy: a mutual attraction. Hematology / Educ Program Am Soc Hematol Am Soc Hematol Educ Program. 2007:473-81.
32. Neuber C, Muller OJ, Hansen FC, Eder A, Witten A, Ruhle F, et al. Paradoxical effects on force generation after efficient beta1-adrenoceptor knockdown in reconstituted heart tissue. J Pharmacol Exp Ther. 2014;349:39-46.
33. Piras BA, O'Connor DM, French BA. Systemic delivery of shRNA by AAV9 provides highly efficient knockdown of ubiquitously expressed GFP in mouse heart, but not liver. PLoS ONE. 2013;8:e75894.
34. Liu Y, Li D, Chen J, Xie J, Bandyopadhyay S, Zhang D, et al. Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. Atherosclerosis. 2006;188:19-27. (Pubitemid 44160702)
35. Yoshioka T, Okada T, Maeda Y, Ikeda U, Shimpo M, Nomoto T, et al. Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice. Gene Ther. 2004;11:1772-9. (Pubitemid 40028538)
36. Khan JA, Cao M, Kang BY, Liu Y, Mehta JL, Hermonat PL. AAV/hSTAT3-gene delivery lowers aortic inflammatory cell infiltration in LDLR KO mice on high cholesterol. Atherosclerosis. 2010;213:59-66.
37. Cao M, Khan JA, Kang BY, Mehta JL, Hermonat PL. Dual AAV/IL-10 plus STAT3 anti-inflammatory gene delivery lowers atherosclerosis in LDLR KO mice, but without increased benefit. Int J Vasc Med. 2012;2012:524235.
38. Li D, Liu Y, Chen J, Velchala N, Amani F, Nemarkommula A, et al. Suppression of atherogenesis by delivery of TGFbeta1ACT using adeno-associated virus type 2 in LDLR knockout mice. Biochem Biophys Res Commun. 2006;344:701-7.
39. Jalkanen J, Leppanen P, Pajusola K, Narvanen O, Mahonen A, Vahakangas E, et al. Adeno-associated virus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor reduces atherosclerotic lesion formation in LDL receptor knockout mice. Mol Ther J Am Soc Gene Ther. 2003;8:903-10. (Pubitemid 38081221)
40. Rowzee AM, Cawley NX, Chiorini JA, Di Pasquale G. Glucagon-like peptide-1 gene therapy. Exp Diabetes Res. 2011;2011:601047.
41. Wang J, Wang F, Xu J, Ding S, Guo Y. Double-strand adenoassociated virus-mediated exendin-4 expression in salivary glands is efficient in a diabetic rat model. Diabetes Res Clin Pract. 2014;103:466-73.
42. Gaddy DF, Riedel MJ, Pejawar-Gaddy S, Kieffer TJ, Robbins PD. In vivo expression of HGF/NK1 and GLP-1 From dsAAV vectors enhances pancreatic ss-cell proliferation and improves pathology in the db/db mouse model of diabetes. Diabetes. 2010;59:3108-16.
43. Burgmaier M, Liberman A, Mollmann J, Kahles F, Reith S, Lebherz C, et al. Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe(-)/(-) mice. Atherosclerosis. 2013;231:427-35.
44. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-26.
45. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-35.
46. Zouein FA, Booz GW. AAV-mediated gene therapy for heart failure: enhancing contractility and calcium handling. F1000Prime Rep. 2013;5:27.
47. Scimia MC, Gumpert AM, Koch WJ. Cardiovascular gene therapy for myocardial infarction. Expert Opin Biol Ther. 2014;14:183-95.
48. Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, et al. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res. 2014;114:101-8. A landmark study evaluating the effects of AAV SERCA gene transfer in patients with heart failure.
49. Lebherz C, Auricchio A, Maguire AM, Rivera VM, Tang W, Grant RL, et al. Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates. Hum Gene Ther. 2005;16:178-86. (Pubitemid 40344210)
50. Su H, Arakawa-Hoyt J, Kan YW. Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model. Proc Natl Acad Sci U S A. 2002;99:9480-5. (Pubitemid 34764639)
51. Pachori AS, Melo LG, Hart ML, Noiseux N, Zhang L, Morello F, et al. Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury. Proc Natl Acad Sci U S A. 2004;101:12282-7. (Pubitemid 39145435)
52. High KA. The gene therapy journey for hemophilia: are we there yet? Hematology / Educ Program Am Soc Hematol Am Soc Hematol Educ Program. 2012;2012:375-81.
53. Gaudet D, Methot J, Dery S, Brisson D, Essiembre C, Tremblay G, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013;20:361-9.